Literature DB >> 25925287

Chloroquine Inhibits Ca(2+) Signaling in Murine CD4(+) Thymocytes.

Jin-Chao Xu1, Yong-Bo Peng, Ming-Yu Wei, Yi-Fan Wu, Donglin Guo, Gangjian Qin, Guangju Ji, Jinhua Shen, Qing-Hua Liu.   

Abstract

BACKGROUND/AIMS: Bitter-tasting chloroquine can suppress T cell activation by inhibiting Ca(2+) signaling. However, the mechanism of inhibition remains largely unclear.
METHODS: In this study, CD4(+) T cells were isolated from the thymus, and the calcium content of CD4(+) thymocytes was measured using fura-2 AM and a TILL imaging system. Pyrazole-3 (Pyr3), thapsigargin (TG), and caffeine were used to assess the effects of chloroquine on the intracellular Ca(2+) content of CD4(+) T cells.
RESULTS: In murine CD4(+) thymocytes, chloroquine decreased the TG-triggered intracellular Ca(2+) increase in a dose-dependent manner. In the absence of chloroquine under Ca(2+)-free conditions (0 mM Ca(2+) and 0.5 mM EGTA), TG induced a transient Ca(2+) increase. After restoration of the extracellular Ca(2+) concentration to 2 mM, a dramatic Ca(2+) increase occurred. This elevation was completely blocked by chloroquine and was markedly inhibited by Pyr3, a selective antagonist of transient receptor potential C3 (TRPC3) channel and stromal interaction molecule (STIM)/Orai channel. Furthermore, the TG-induced transient Ca(2+) increase under Ca(2+)-free conditions was eliminated in the presence of chloroquine. Chloroquine also blocked the dialyzed inositol-1,4,5-trisphosphate (IP3)-induced intracellular Ca(2+) increase. However, chloroquine was not able to decrease the caffeine-induced Ca(2+) increase.
CONCLUSION: These data indicate that chloroquine inhibits the elevation of intracellular Ca(2+) in thymic CD4(+) T cells by inhibiting IP3 receptor-mediated Ca(2+) release from intracellular stores and TRPC3 channel-mediated and/or STIM/Orai channel-mediated Ca(2+) influx.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25925287     DOI: 10.1159/000374058

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  7 in total

1.  Chloroquine is a potent pulmonary vasodilator that attenuates hypoxia-induced pulmonary hypertension.

Authors:  Kang Wu; Qian Zhang; Xiongting Wu; Wenju Lu; Haiyang Tang; Zhihao Liang; Yali Gu; Shanshan Song; Ramon J Ayon; Ziyi Wang; Kimberly M McDermott; Angela Balistrieri; Christina Wang; Stephen M Black; Joe G N Garcia; Ayako Makino; Jason X-J Yuan; Jian Wang
Journal:  Br J Pharmacol       Date:  2017-10-02       Impact factor: 8.739

2.  Chloroquine Suppresses the Development of Hypertension in Spontaneously Hypertensive Rats.

Authors:  Cameron G McCarthy; Camilla F Wenceslau; Styliani Goulopoulou; Babak Baban; Takayuki Matsumoto; R Clinton Webb
Journal:  Am J Hypertens       Date:  2016-09-13       Impact factor: 2.689

3.  Chloroquine inhibits human CD4+ T-cell activation by AP-1 signaling modulation.

Authors:  Ralf L J Schmidt; Sabrina Jutz; Katrin Goldhahn; Nadine Witzeneder; Marlene C Gerner; Doris Trapin; Georg Greiner; Gregor Hoermann; Guenter Steiner; Winfried F Pickl; Heinz Burgmann; Peter Steinberger; Franz Ratzinger; Klaus G Schmetterer
Journal:  Sci Rep       Date:  2017-02-07       Impact factor: 4.379

4.  Chloroquine inhibits Ca2+ permeable ion channels-mediated Ca2+ signaling in primary B lymphocytes.

Authors:  Yi-Fan Wu; Ping Zhao; Xi Luo; Jin-Chao Xu; Lu Xue; Qi Zhou; Mingrui Xiong; Jinhua Shen; Yong-Bo Peng; Meng-Fei Yu; Weiwei Chen; Liqun Ma; Qing-Hua Liu
Journal:  Cell Biosci       Date:  2017-05-23       Impact factor: 7.133

Review 5.  Hydroxychloroquine in rheumatic autoimmune disorders and beyond.

Authors:  Eliise Laura Nirk; Fulvio Reggiori; Mario Mauthe
Journal:  EMBO Mol Med       Date:  2020-07-26       Impact factor: 12.137

6.  Exploring the risk factors for ischemic cerebrovascular disease in systemic lupus erythematosus: A single-center case-control study.

Authors:  Li Su; Zhigang Qi; Shaochen Guan; Lian Wei; Yi Zhao
Journal:  Front Immunol       Date:  2022-09-27       Impact factor: 8.786

Review 7.  Chloroquine to fight COVID-19: A consideration of mechanisms and adverse effects?

Authors:  Xiping Zhan; Sharon Dowell; Ying Shen; Dexter L Lee
Journal:  Heliyon       Date:  2020-09-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.